Claims for Patent: 9,889,118

Summary for Patent: 9,889,118

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Gilbert; Julian Clive (Cambridgeshire, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridgeshire, GB)
Assignee:	Acacia Pharma Limited (Cambridgeshire, GB)
Application Number:	15/374,174
Patent Claims:	1. A method for the prevention and/or treatment of post-operative nausea and vomiting, comprising administering amisulpride at a dose of less than 50 mg to a subject of a surgical procedure and in need of such prevention and/or treatment. 2. The method of claim 1, wherein the subject is also administered an emetogenic agent. 3. The method of claim 2, wherein the emetogenic agent is an opiate. 4. The method of claim 2, wherein the emetogenic agent is morphine. 5. The method of claim 1, wherein the subject is a human. 6. The method of claim 1, wherein the amisulpride is in the form of an acceptable pharmaceutical salt. 7. The method of claim 1, wherein the amisulpride is administered in combination with another anti-emetic drug. 8. The method of claim 7, wherein the another anti-emetic drug is a 5HT3 antagonist. 9. The method of claim 8, wherein the 5HT3 antagonist is ondansetron. 10. The method of claim 1, wherein the amisulpride is administered in combination with dexamethasone. 11. The method of claim 1, wherein the amisulpride is administered at a dose of 1 mg to 35 mg. 12. The method of claim 1, wherein the subject has received an anesthetic. 13. The method of claim 1, wherein the surgical procedure is chosen from procedures of the eye or ear, laparoscopic cholecystectomy, hysterectomy, breast surgery, abdominal surgery, and gynecological surgery. 14. The method of claim 1, wherein the amisulpride is administered by intravenous injection, intramuscular injection, or subcutaneous injection. 15. The method of claim 1, wherein the amisulpride is administered orally. 16. The method of claim 1, wherein the amisulpride is administered sublingually or intranasally. 17. The method of claim 1, wherein the amisulpride is administered topically. 18. The method of claim 1, wherein the amisulpride is administered transdermally. 19. The method of claim 1, wherein the amisulpride is administered rectally. 20. The method of claim 1, wherein the amisulpride is (S-)-amisulpride.